TABLE 1.
Published studies of primary prophylaxis in children
| Design | n | Follow-up | % Bleeding | |
|---|---|---|---|---|
| β-Blockers | ||||
| Shashidhar et al (46) | CS | 17 | 3 y | 35 |
| Ozsoylu et al (47) | CS | 45 | 5 y | 16 |
| Erkan et al (49) | CS | 10 | 5.2 y | 10 |
| EST | ||||
| Paquet (57) | CS | 2 | 10 y | 0 |
| Howard et al (58) | CS | 17 | 2.5 y | 0 |
| Maksoud et al (59) | CS | 26 | 2.4 y | 42 |
| Goncalves et al (36) | RCT | 100 | 4.5 y | 6% EST vs 42% control |
| Duché | CS | 13 | 8 mo | 8 |
| EVL | ||||
| Cano et al (60) | CS | 4 | Not given | 0 |
| Sasaki et al (61) | CS | 9 | 23 mo | 10 |
| Celinska-Cedro et al (62) | CS | 37 | 16 mo | 0 |
CS = case series; EST = endoscopic sclerotherapy; EVL = endoscopic variceal ligation; RCT = randomized controlled trial.